Pharma Sector

The record date for the share buyback has been set as July 30, 2024. Promoters will also participate in the share buyback.

The company stated that its production facility in Bharuch successfully completed its USFDA inspection with zero 483 findings.

The Delhi-based startup has signed in-licensing arrangements with Novartis for the heart failure treatment Neptaz.

On February 6, 2023, Cipla informed exchanges that I-T department officials had searched some of company offices and manufacturing units.

According to the terms of the agreement, Lupin may receive up to $84 million in total payment based on future dependent milestones.

According to the corporation, the observations have no influence on business continuity or supplies to the US market.

The inspection finished with no observations, and the facility was classified as "No Action Indicated" (NAI).

It has entered into a share purchase agreement to acquire a 100% equity stake in Chalasani Hospitals Pvt Ltd.

Currently, more than 70 Kaya skin clinics nationwide and some of the top e-commerce platforms carry Kaya's products.

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.